Objective: The mechanism of Astragalus-Bupleurum treatment for hyperthyroidism was investigated by network pharmacology and molecular docking methods. Methods: TCMSP database was used to screen out the active constituents of Astragalus bupleurum and their corresponding targets with bioavailability (OB)≥30% and drug index (DL)≥0.18. Both GeneCards, DisGeNET, TTD and Drugbank databases were used to search the relevant targets with the key words Hyperthyroidism; To obtain the intersection targets between TCM and diseases, the key targets were selected using the "Degree", "Betweenness" and "Closeness" in Cytoscape software, and the key target information was obtained on the DAVID platform to construct GO functional enrichment and KEGG pathway enrichment analysis. Autodock Tools 1.5.7 software was used to conduct molecular docking of core targets and their corresponding active components. Results: The results showed that 20 active ingredients (224 targets) of Astragalus and 17 active ingredients (193 targets) of Bupleurum were obtained. There were 1358 targets associated with hyperthyroidism. Intersection mapping obtained 76 intersection targets. Eighteen core targets were selected by the plug-in for GO functional enrichment analysis and 306 items were obtained, including 244 biological process items, 20 cell localization items and 42 molecular function items. Ninety-six signaling pathways were annotated by KEGG pathway, such as HIF-1 signaling pathway, IL-17 signaling pathway, TNF signaling pathway, etc. Molecular docking results showed that the key targets of AKT1, IL-6, TNF and IL-1β had good affinity with the corresponding active ingredients. Conclusion: Radix Astragalus Bupleurum is effective in treating hyperthyroidism through multi-component, multi-target and multi-pathway synergies. This study provides sufficient theoretical basis for subsequent research.